Alector Files 8-K on Financial Condition, Operations

TL;DR

**Alector just dropped an 8-K on its financial results, so expect some market reaction.**

AI Summary

Alector, Inc. filed an 8-K on January 16, 2024, to report on its 'Results of Operations and Financial Condition.' This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the company's current health and future prospects. For shareholders, this matters because it offers transparency into how Alector is managing its finances and operating its business, directly impacting the stock's perceived value and potential for growth or decline.

Why It Matters

This filing provides an update on Alector's financial health, which is essential for investors to assess the company's performance and make informed decisions about their investment.

Risk Assessment

Risk Level: medium — While an 8-K for 'Results of Operations and Financial Condition' is standard, the specific details within could reveal positive or negative financial performance, introducing moderate risk.

Analyst Insight

Investors should review the full 8-K filing for specific financial details to understand Alector's current performance and potential implications for its stock price.

Key Players & Entities

• Alector, Inc. (company) — the registrant filing the 8-K
• January 16, 2024 (date) — date of earliest event reported
• 001-38792 (string) — Commission File Number
• ALEC (string) — trading symbol for Alector, Inc.
• The Nasdaq Stock Market LLC (string) — exchange where Alector's common stock is registered

FAQ

From the Filing

0001193125-24-008551.txt : 20240116 0001193125-24-008551.hdr.sgml : 20240116 20240116160453 ACCESSION NUMBER: 0001193125-24-008551 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240116 ITEM INFORMATION: Results of Operations and Financial Condition FILED AS OF DATE: 20240116 DATE AS OF CHANGE: 20240116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alector, Inc. CENTRAL INDEX KEY: 0001653087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822933343 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38792 FILM NUMBER: 24535168 BUSINESS ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-231-5660 MAIL ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Alector LLC DATE OF NAME CHANGE: 20150915 8-K 1 d110116d8k.htm 8-K 8-K false 0001653087 0001653087 2024-01-16 2024-01-16     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024     Alector, Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-38792   82-2933343 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   131 Oyster Point Blvd.     Suite 600     South San Francisco , California     94080 (Address of Principal Executive Offices)     (Zip Code) Registrant’s Telephone Number, Including Area Code: (415) 231-5660 (Former Name or Former Address, if Changed Since Last Report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock   ALEC   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐       Item 2.02 Results of Operations and Financial Condition. On January 16, 2024, Alector, Inc. (the “Company”) announced its preliminary estimate of cash, cash equivalents, and short-term investments as of December 31, 2023. Based upon preliminary estimates and information available to the Company as of the date of this Form 8-K, it had approximately $549 million of cash, cash equivalents, and short-term investments as of December 31, 2023, which the Company believes will enable it to fund its operating expenses and capital expenditure requirements into